New Medicines and Clinical Trials for Aplastic Anemia: How to Decide Whether a Study May Suit You

If you see news about a new medicine or a trial poster for aplastic anemia, first share the link or registration number with your hematologist. Ask them to review your diagnosis, recent blood counts, and previous treatment to decide whether contacting the study center is worthwhile and whether it is safe to wait for screening. If you already have a fever, bleeding, or a worsening infection, contact your treatment team immediately. If symptoms are severe or you cannot reach the team promptly, go to the nearest emergency department. Do not wait for a trial response.

Key points

• Research findings, medicine approval in a particular jurisdiction, and trial registration answer different questions. Even if a registry says a study is recruiting, the specific center must confirm whether the relevant cohort is accepting patients and whether you can be screened.
• The severity of aplastic anemia, whether you are previously untreated or have received treatment, infections, and donor availability all affect the discussion. Low blood counts or a disease name alone cannot establish the diagnosis or trial eligibility.
• You still need arrangements for transfusions, infection care, and blood count monitoring during a study. Do not stop medicines yourself or delay necessary treatment to meet trial requirements.
• Before traveling to China, separately confirm acceptance for a routine outpatient appointment, study prescreening, formal screening, and enrollment. Each step may have different requirements.

First confirm your condition and whether you can wait

Ask your hematologist to document whether you have acquired aplastic anemia or are still being assessed for other bone marrow failure disorders, how severe your condition is, and which tests remain incomplete. Bone marrow tests, blood counts, and the necessary tests to distinguish between possible diagnoses help doctors make this assessment; low blood counts alone cannot confirm aplastic anemia. Some inherited bone marrow failure disorders require different assessments, so be sure to tell your doctor about your family history and any previous abnormalities. British Society for Haematology guideline on diagnosing and managing aplastic anemia

Prepare a one-page summary: recent complete blood counts and bone marrow reports, transfusion frequency, infections or bleeding, current medicines, and other medical conditions. List treatments by date, including antithymocyte globulin (ATG), cyclosporine, medicines that stimulate blood cell production, and transplantation, with the response and reasons for stopping. Attach HLA typing and donor results if available. If results are unavailable, write “not tested” or “awaiting review.”

Agree with your usual treatment team on who will manage blood count checks, transfusions, and infections while you wait, when you will be reassessed, and what to do if you can no longer wait. Ask your doctor to write down, based on your condition, the symptoms or thresholds that require help for fever, chills, or bleeding, how quickly to seek help, daytime and nighttime contact numbers, and which emergency department to attend if you cannot reach the team. Go to the nearest emergency department immediately for heavy bleeding or bleeding that will not stop. For fever, chills, or worsening infection, also contact your treatment team immediately; if you cannot reach them, go to the nearest emergency department. Do not delay care while waiting for a trial response, and do not change your medicines yourself. US National Cancer Institute: Infection; US National Heart, Lung, and Blood Institute: Low Platelets

When you read “a new medicine works,” first check what the study answers

Treatment discussions for acquired severe aplastic anemia may include immunosuppressive therapy, allogeneic hematopoietic stem cell transplantation, and supportive care. The choice depends on age, disease severity, donors, infections, and individual circumstances. Guidelines and medicine availability may also differ between countries. ASH 2026 guideline

For example, the RACE randomized trial studied patients with previously untreated severe aplastic anemia. One group received horse ATG plus cyclosporine; the other received eltrombopag in addition to those medicines. At 3 months, 10% and 22%, respectively, achieved the study-defined complete hematologic response. At 6 months, overall response, including complete or partial response, was 41% and 68%, respectively. The study took place in six European countries and enrolled patients aged 15 years and older who were not suitable for first-line transplantation. These results apply to a specific population and specific assessment times. They cannot be treated as your personal chance of success or prove that all regimens containing eltrombopag are equivalent. Original RACE paper

SOAR was a single-arm phase II study of eltrombopag plus cyclosporine in adults with previously untreated severe acquired aplastic anemia. Because it had no concurrent randomized control group, it cannot establish that a regimen without ATG is equivalent to or better than other regimens. If a hospital cannot provide a particular type of ATG, ask whether this is due to supply or because the doctor considers it unsuitable. Then ask your hematologist to discuss available options and arrangements while waiting. Original SOAR study · Registry record

In 2026, the RACE investigators published a two-year analysis of the same randomized trial. Complete hematologic response results were better in the group receiving eltrombopag, but the difference in overall survival between the groups was not statistically significant. Two years is still too short to assess risks that may emerge many years later. Some patients also received other treatments during this period. Ask your doctor to discuss further treatment and monitoring in light of these conditions, and do not treat an early response as a guarantee of long-term outcomes. RACE two-year analysis

When reading a study, check whether patients were previously untreated, how severe their disease was, which exact regimens were compared, the outcomes measured, and when they were assessed. A hematologic response does not mean a permanent cure. Also ask how long responses last, whether transfusions are still needed, and how relapse, clonal evolution, and side effects are monitored. Study populations and follow-up periods differ, so percentages cannot be used to rank studies directly. Long-term follow-up of another single-arm study

How can you check whether a medicine can be used in China?

The US FDA prescribing information for PROMACTA includes first-line use with standard immunosuppressive therapy in certain patients with severe aplastic anemia, as well as use in severe aplastic anemia with an insufficient response to immunosuppressive therapy. Public records from China’s National Medical Products Administration show that an indication for “severe aplastic anemia with an insufficient response to previous immunosuppressive therapy” was added for eltrombopag olamine tablets from Novartis Pharma Schweiz AG. These two documents concern different jurisdictions, products, and uses. US approval or a published paper does not establish that all products in China are approved for the same first-line use. US prescribing information · Chinese National Medical Products Administration record

Ask the hematology department and pharmacist at the hospital you plan to attend to check the indication, supply, and cost against the specific product, its current Chinese prescribing information, and your circumstances. A medicine’s use for another condition involving low platelets does not establish that it is equally effective for aplastic anemia. Eltrombopag must be taken at specified intervals from certain mineral-containing medicines, supplements, and foods, and liver function must be monitored. Ask a pharmacist for instructions based on your actual formulation and complete medicine list. Do not switch medicines or adjust doses yourself. MedlinePlus

What are transplant studies trying to change?

Transplant studies for aplastic anemia may focus on donor selection, cell source, conditioning treatment, or prevention of immune complications. Ask the transplant team to explain which parts are added for research and which are routine care; whether potential donors have had HLA testing; when the assessment is expected to be completed; and how infection, transplant failure, and graft-versus-host disease will be monitored. “Haploidentical” describes the donor matching relationship, while bone marrow, peripheral blood, and cord blood describe cell sources. They should not be treated as the same measure. EBMT Handbook · EBMT 2025 recommendations

Before traveling to China, also ask the center whether the donor can take part in assessment and donation, the expected length of stay and caregiver arrangements, how complications will be managed, and how follow-up will work after you return home. For general transplant preparation, see the haploidentical transplant guide and the bone marrow and hematopoietic stem cell transplant guide.

What must you confirm between finding a registry record and enrolling?

Search ClinicalTrials.gov using the full NCT number. For drug trials in China, you can search the Drug Clinical Trial Registration and Information Disclosure Platform and also check the Chinese Clinical Trial Registry. Record the study name, protocol number, study population, intervention, comparator, primary outcome, locations, and update date. These platforms differ in coverage. Registration itself does not prove that a treatment works or that a patient can enroll.

For example, NCT07345000 is registered as a phase III randomized study in previously untreated severe aplastic anemia, comparing romiplostim N01 plus standard immunosuppression with placebo plus standard immunosuppression. The record was last updated on January 15, 2026, when its overall status was “not yet recruiting.” This older record may be out of date and cannot establish whether places are available now. Ask the target center to check the specific cohort. The registry record for another study in moderate aplastic anemia, NCT01328587, was updated to “completed” in April 2026 and should not be treated as a current enrollment opportunity.

Once you have identified the specific hospital campus, you can send:

The patient lives in [country/region]. Their diagnosis and disease severity are [ ], recent blood counts and transfusion needs are [ ], and previous treatments and dates are [ ]. We would like to ask about [registration number, protocol number, hospital campus]: Is the relevant cohort currently accepting patients for prescreening? Do you accept patients from outside China? Can you review records remotely first, and what reports and languages are required? If an in-person visit is needed, is the appointment for routine outpatient care or study screening?

First ask which secure channel the hospital approves for receiving records, then submit the required documents. A hospital’s willingness to see you does not mean the study will offer prescreening; passing prescreening and signing informed consent do not mean you are formally enrolled. The study doctor must complete screening and confirm eligibility under the specific protocol. Before signing, ask about treatment in each group, random assignment, possible benefits and risks, other options, the testing schedule, your right to withdraw, and ethics committee contact details. Informed consent should be completed before any research-specific procedures begin. Measures for Ethical Review of Research

If the protocol requires stopping a medicine or a washout period, ask the study doctor to provide the requirements in writing, then have your usual treating doctor assess whether you can safely wait. Do not stop medicines yourself. Before formal screening, ask the study center who will notify you of the results and when, when you can obtain test reports if you are not eligible, and whom to contact if you receive no response. Share the results with your usual hematologist and arrange reassessment by the latest time agreed in advance. If your condition cannot wait, seek care immediately under your backup plan.

How can you clarify costs and follow-up care?

Article 8 of China’s Regulations for the Implementation of the Drug Administration Law states that drug clinical trial sponsors and trial institutions must not charge participants fees related to the clinical trial. Ask the study center to explain the rules that apply to this study and provide a written breakdown of who pays for study-related items, routine medical care, travel, accommodation, and interpreting. Also ask what happens if screening is unsuccessful, you withdraw early, or harm occurs. Do not decide solely on claims that participation is “free” or “self-funded.” State Council regulations

Before departure, obtain the screening and follow-up schedule. Confirm which tests must be done at the study center, whether results from other hospitals are accepted, and how long you are expected to stay locally. Ask how medicines and follow-up will be arranged after the study ends or you withdraw. Agree with your hematologist where you live on who will repeat tests, explain results, and manage fever or bleeding. For treatment-related harm and compensation, ask the center for a written explanation and ethics committee contact details.

Frequently asked questions

Must I try all routine treatments before joining?

Not necessarily. Some studies enroll only previously untreated patients; others require specific previous treatments. Give the study team your treatment dates and responses so they can check them against the protocol.

Can results in severe aplastic anemia be applied to moderate aplastic anemia?

Not directly. Disease severity, study populations, and protocols differ. Ask your doctor to explain how the relevant study relates to your condition.

I have passed remote prescreening. Can I book a nonrefundable flight immediately?

First confirm the hospital campus, formal screening date, requirements for accepting patients from outside China, tests, and stay arrangements. Formal screening may still find that you are not eligible.

If the donor is a relative, are they definitely suitable for transplantation?

Not necessarily. Being related does not replace HLA testing and an independent health assessment of the donor. The transplant team must also assess the patient and the treatment plan.

What if an organization promises guaranteed enrollment or a cure if I pay?

Pause payment and independently contact the study team through the registry page or hospital’s official website. Verify the protocol, institution, charges, and ethics review. Clinical trials cannot guarantee an individual benefit.

Can I continue treatment if I do not join or withdraw partway through?

Before withdrawing, contact the study doctor and your usual hematologist to confirm safe medicine discontinuation, tests, and the handover of further treatment. You can ask the ethics committee to explain participants’ rights.

If a medicine is approved abroad, can the same regimen be used in China?

Not necessarily. Ask the hospital to check the specific product’s current Chinese prescribing information, supply, and your circumstances. Overseas approvals, published papers, and Chinese approvals each have their own scope.

Sources

Sources and registry records checked: November 6, 2026. Study and supply status may change and must be reconfirmed with the specific center. Links appear in the relevant paragraphs. The hospital must still check current Chinese product prescribing information, the specific campus’s international patient policy, and costs for the particular study.

Key sources include: ASH 2026 guideline, British Society for Haematology guideline on diagnosis and management, RACE randomized study, SOAR study, Chinese National Medical Products Administration drug record, and Regulations for the Implementation of the Drug Administration Law.